Camizestrant Significantly Improved Progression-Free Survival vs. Faslodex in SERENA-2 Phase II Trial in Advanced ER-Positive Breast Cancer

Positive high-level results from the SERENA-2 Phase II trial showed that AstraZeneca’s next-generation oral selective estrogen receptor degrader camizestrant met the primary endpoint of demonstrating a statistically significant and clinically meaningful progression-free survival benefit versus Faslodex (fulvestrant) in post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer.